This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
infl uenza | 374 |
respiratory syndrome | 274 |
acute respiratory | 220 |
severe acute | 199 |
public health | 194 |
syndrome coronavirus | 139 |
viral load | 131 |
care workers | 118 |
middle east | 110 |
infectious diseases | 108 |
hong kong | 107 |
east respiratory | 93 |
symptom onset | 87 |
novel coronavirus | 78 |
avian infl | 76 |
respiratory tract | 72 |
cell responses | 68 |
cov infection | 66 |
diff erent | 62 |
antibody responses | 61 |
avian influenza | 60 |
immunity passports | 58 |
rotavirus infection | 55 |
sars coronavirus | 55 |
human coronavirus | 53 |
coronavirus disease | 53 |
human beings | 51 |
nitazoxanide mg | 50 |
uenza virus | 49 |
infect dis | 49 |
lancet infect | 49 |
doc id | 48 |
cord uid | 48 |
dis doi | 48 |
coronavirus infection | 46 |
infection control | 45 |
eff ective | 45 |
saudi arabia | 43 |
fi gure | 43 |
infectious disease | 43 |
dromedary camels | 43 |
spike protein | 42 |
clinical trials | 42 |
fi rst | 41 |
pcr testing | 40 |
immune response | 37 |
eff ects | 37 |
influenza virus | 37 |
contact tracing | 37 |
treatment group | 37 |
confi rmed | 37 |
like receptor | 36 |
close contacts | 36 |
neuraminidase inhibitors | 35 |
paediatric patients | 35 |
eff ect | 35 |
influenza viruses | 34 |
uenza viruses | 34 |
identifi ed | 33 |
neutralising antibodies | 33 |
antibody response | 33 |
ebola virus | 31 |
virus infection | 31 |
viral shedding | 30 |
per ml | 30 |
control measures | 30 |
coronavirus oc | 30 |
abattoir workers | 30 |
cohort study | 30 |
severe disease | 30 |
disease control | 29 |
natural products | 29 |
highly pathogenic | 29 |
upper respiratory | 29 |
cruise ship | 28 |
blood samples | 28 |
common cold | 28 |
copies per | 28 |
newborn babies | 27 |
air travel | 27 |
global health | 27 |
intensive care | 26 |
mass gatherings | 26 |
interferon alfa | 26 |
antibody titres | 26 |
serum samples | 25 |
competing interests | 25 |
immune responses | 25 |
effi cacy | 25 |
neutralising antibody | 25 |
patients infected | 24 |
human cases | 24 |
based surveillance | 24 |
pathogenic avian | 24 |
viral loads | 24 |
healthcare workers | 24 |
lower respiratory | 24 |
clinical features | 23 |
associated coronavirus | 23 |
viral infections | 23 |
viral rna | 23 |
health measures | 23 |
pandemic infl | 22 |
controlled trial | 22 |
confirmed cases | 22 |
innate immune | 22 |
diff erences | 22 |
systematic review | 22 |
risk factors | 22 |
aged years | 21 |
virus vaccine | 21 |
data collection | 21 |
bovine coronavirus | 21 |
clinical trial | 21 |
personal view | 21 |
signifi cant | 21 |
arabian peninsula | 21 |
communicable diseases | 21 |
placebo group | 20 |
tract infections | 20 |
health security | 20 |
serological testing | 20 |
fever without | 20 |
without source | 20 |
rotavirus infections | 20 |
mg treatment | 20 |
suspected meningitis | 20 |
camel milk | 19 |
attack rate | 19 |
health risks | 18 |
severe mers | 18 |
signifi cantly | 18 |
diff erence | 18 |
respiratory symptoms | 18 |
sore throat | 18 |
distress syndrome | 18 |
ill patients | 18 |
critically ill | 18 |
alveolar damage | 18 |
respiratory distress | 18 |
united states | 17 |
seasonal infl | 17 |
eff ectiveness | 17 |
diffuse alveolar | 17 |
human transmission | 17 |
influenza vaccines | 17 |
infected patients | 17 |
randomised controlled | 17 |
viral infection | 17 |
throat swab | 17 |
marine natural | 17 |
rbd igg | 17 |
emerging infectious | 17 |
pegylated interferon | 17 |
disease transmission | 17 |
viral replication | 16 |
human infection | 16 |
data analysis | 16 |
serum antibody | 16 |
adverse events | 16 |
identifi cation | 16 |
health care | 16 |
molecular testing | 16 |
emergency department | 16 |
animal models | 16 |
adult patients | 16 |
severe respiratory | 16 |
risk assessment | 16 |
protective immunity | 15 |
posterior oropharyngeal | 15 |
case series | 15 |
serial interval | 15 |
lopinavir ritonavir | 15 |
nd nd | 15 |
serology tests | 15 |
acquired pneumonia | 15 |
neuraminidase inhibitor | 15 |
human coronaviruses | 15 |
close contact | 15 |
resolution ct | 15 |
observational cohort | 15 |
least one | 15 |
respiratory failure | 15 |
convalescent plasma | 14 |
may also | 14 |
ipc measures | 14 |
saliva samples | 14 |
clinical presentation | 14 |
viruses isolated | 14 |
live poultry | 14 |
prospective study | 14 |
protective equipment | 14 |
care settings | 14 |
tested positive | 14 |
severe infl | 14 |
receptor binding | 14 |
increased risk | 13 |
pandemic influenza | 13 |
oropharyngeal saliva | 13 |
biological agents | 13 |
cov neutralising | 13 |
full access | 13 |
enterovirus pcr | 13 |
closely related | 13 |
log copies | 13 |
interpreted data | 13 |
clinical characteristics | 13 |
nasal congestion | 13 |
hospitalized patients | 13 |
mg group | 13 |
poultry markets | 13 |
study design | 13 |
binding domain | 13 |
human mers | 13 |
respiratory infections | 13 |
syndromic surveillance | 13 |
comparator group | 13 |
high viral | 13 |
oc antigen | 13 |
disease severity | 13 |
one patient | 13 |
searched pubmed | 13 |
world health | 13 |
mild disease | 13 |
health organization | 13 |
infected individuals | 13 |
nine patients | 12 |
marine sponge | 12 |
serological evidence | 12 |
like receptors | 12 |
high risk | 12 |
incubation period | 12 |
camel mers | 12 |
personal protective | 12 |
bacillus anthracis | 12 |
search terms | 12 |
fi nal | 12 |
patients admitted | 12 |
wild birds | 12 |
respiratory syncytial | 12 |
mechanical ventilation | 12 |
community transmission | 12 |
canary islands | 12 |
diagnostic tests | 12 |
nucleocapsid protein | 12 |
risk communication | 12 |
electron microscopy | 12 |
camel sera | 12 |
infectious virus | 12 |
vitro activity | 12 |
like illness | 12 |
mers coronavirus | 12 |
like disease | 12 |
data interpretation | 12 |
cov antigen | 12 |
three clusters | 12 |
syncytial virus | 12 |
nasal discharge | 12 |
previous infection | 12 |
urgently needed | 12 |
cov infections | 12 |
diamond princess | 12 |
emergency response | 12 |
naturally occurring | 11 |
vaccine development | 11 |
sars outbreak | 11 |
benefi cial | 11 |
care worker | 11 |
diff erential | 11 |
confirmed covid | 11 |
mass gathering | 11 |
novel human | 11 |
infl ammatory | 11 |
sample size | 11 |
care unit | 11 |
cerebrospinal fluid | 11 |
aff ect | 11 |
large number | 11 |
princess cruise | 11 |
symptomatic patients | 11 |
also known | 11 |
young children | 11 |
even though | 11 |
haemorrhagic fever | 11 |
resistant tuberculosis | 11 |
asymptomatic patients | 11 |
csf specimens | 11 |
swab rt | 11 |
immune system | 11 |
uncomplicated infl | 11 |
virus vaccines | 11 |
clinical management | 11 |
confl icts | 11 |
diffi cult | 11 |
body temperature | 11 |
reverse genetics | 11 |
phylogenetic analysis | 11 |
emergency committee | 10 |
sex workers | 10 |
healthy adults | 10 |
might also | 10 |
load monitoring | 10 |
respiratory illness | 10 |
one study | 10 |
th century | 10 |
two doses | 10 |
cell lines | 10 |
observational study | 10 |
innate immunity | 10 |
nasopharyngeal swabs | 10 |
health issues | 10 |
sialic acid | 10 |
necrosis factor | 10 |
risks associated | 10 |
rotavirus gastroenteritis | 10 |
nosocomial transmission | 10 |
age groups | 10 |
serum antibodies | 10 |
european union | 10 |
coronavirus replication | 10 |
virus neutralisation | 10 |
antiviral drugs | 10 |
serological assays | 10 |
us centers | 10 |
antiviral activity | 10 |
new drugs | 10 |
research agenda | 10 |
monoclonal antibodies | 10 |
colleagues reported | 10 |
transmission dynamics | 10 |
neutralizing antibody | 10 |
human infections | 10 |
tract infection | 10 |
nasopharyngeal swab | 10 |
family gathering | 10 |
early detection | 10 |
international health | 10 |
anthrax vaccine | 10 |
secondary attack | 10 |
tested negative | 10 |
cleavage site | 10 |
epithelial cells | 10 |
infected individual | 9 |
treatment regimens | 9 |
viral clearance | 9 |
septic shock | 9 |
natural history | 9 |
health regulations | 9 |
cell transplantation | 9 |
positive result | 9 |
medical care | 9 |
rna viruses | 9 |
decision making | 9 |
respiratory specimens | 9 |
acute gastroenteritis | 9 |
defi ned | 9 |
structural proteins | 9 |
among adults | 9 |
twice daily | 9 |
influenza vaccine | 9 |
cases reported | 9 |
rmed infl | 9 |
human influenza | 9 |
human genome | 9 |
community outbreak | 9 |
malaria control | 9 |
direct contact | 9 |
epidemic potential | 9 |
within days | 9 |
virus particles | 9 |
antiviral therapy | 9 |
risk management | 9 |
south korea | 9 |
fungal infections | 9 |
defi nition | 9 |
united arab | 9 |
family cluster | 9 |
tumour necrosis | 9 |
antibody titre | 9 |
virus infections | 9 |
colleagues found | 9 |
mild symptoms | 9 |
acute phase | 9 |
infection among | 9 |
respiratory infection | 9 |
confi rmation | 9 |
global public | 9 |
virus disease | 9 |
dna vaccine | 9 |
camel urine | 9 |
specifi city | 9 |
enterovirus infection | 9 |
arab emirates | 9 |
emergency departments | 9 |
family members | 9 |
fi nding | 9 |
respiratory disease | 9 |
person transmission | 9 |
reactive protein | 9 |
mild cases | 9 |
health authorities | 9 |
amino acid | 8 |
trigeminal nerves | 8 |
per year | 8 |
four patients | 8 |
shenzhen cdc | 8 |
drinking camel | 8 |
coronavirus pneumonia | 8 |
index case | 8 |
serological analysis | 8 |
west african | 8 |
communicable disease | 8 |
effi cient | 8 |
infl uence | 8 |
global spread | 8 |
among patients | 8 |
severe cases | 8 |
developed symptoms | 8 |
exposed individuals | 8 |
clinical studies | 8 |
care providers | 8 |
hospital admission | 8 |
rectal swabs | 8 |
antiviral treatment | 8 |
single nucleotide | 8 |
infectious agent | 8 |
aff ected | 8 |
antibody levels | 8 |
stranded rna | 8 |
acute uncomplicated | 8 |
vaccine candidate | 8 |
serological tests | 8 |
antiviral agents | 8 |
peripheral blood | 8 |
infection prevention | 8 |
informed consent | 8 |
respiratory secretions | 8 |
nasal epithelium | 8 |
literature search | 8 |
infected cells | 8 |
case reports | 8 |
related virus | 8 |
will also | 8 |
social distancing | 8 |
poc tests | 8 |
past infection | 8 |
glass changes | 8 |
exposure prophylaxis | 8 |
final responsibility | 8 |
rhesus macaques | 8 |
herpes simplex | 8 |
logistic regression | 8 |
three patients | 8 |
fi eld | 8 |
fi ndings | 8 |
peak viral | 8 |
inactivated sars | 8 |
profi le | 8 |
clinical course | 8 |
human rotavirus | 8 |
sars epidemic | 8 |
negative bacteria | 8 |
small number | 8 |
dna vaccines | 8 |
patients without | 8 |
viral particles | 8 |
study date | 8 |
retrospective cohort | 8 |
high prevalence | 8 |
rapid serology | 8 |
antibody testing | 8 |
care facilities | 8 |
urine samples | 8 |
case defi | 8 |
respiratory virus | 8 |
drug administration | 7 |
aspergillus fumigatus | 7 |
lung injury | 7 |
duck singapore | 7 |
igg antibodies | 7 |
patients aged | 7 |
vaccine candidates | 7 |
avian species | 7 |
negative rt | 7 |
virus strains | 7 |
host response | 7 |
less likely | 7 |
one dose | 7 |
corresponding author | 7 |
lobe changes | 7 |
viral haemorrhagic | 7 |
surface spike | 7 |
attack rates | 7 |
household contacts | 7 |
antimicrobial therapy | 7 |
toxic effects | 7 |
health research | 7 |
disease caused | 7 |
diff erentiation | 7 |
containment efforts | 7 |
institutional review | 7 |
antifungal activity | 7 |
clinical use | 7 |
coronavirus emc | 7 |
urgent need | 7 |
rst dose | 7 |
colleagues noted | 7 |
influenza pandemic | 7 |
infections caused | 7 |
bioterrorism preparedness | 7 |
streptococcus pneumoniae | 7 |
median time | 7 |
cell culture | 7 |
health emergencies | 7 |
age group | 7 |
antibody tests | 7 |
immunologically naive | 7 |
functional receptor | 7 |
crew members | 7 |
marine environment | 7 |
fi brosis | 7 |
previously described | 7 |
case fatality | 7 |
genetic polymorphisms | 7 |
care staff | 7 |
clinical assessment | 7 |
care units | 7 |
although many | 7 |
articles published | 7 |
determine whether | 7 |
cell count | 7 |
general population | 7 |
without exposure | 7 |
controlled clinical | 7 |
blood enterovirus | 7 |
review board | 7 |
commercial assays | 7 |
samples taken | 7 |
serum igg | 7 |
plaque reduction | 7 |
pandemic virus | 7 |
mammalian cell | 7 |
respiratory viruses | 7 |
virus epidemic | 7 |
severe symptoms | 7 |
care system | 7 |
active monitoring | 7 |
serial viral | 7 |
two patients | 7 |
antigen detection | 7 |
develop symptoms | 7 |
statistical analyses | 7 |
first week | 7 |
mildly symptomatic | 7 |
emerging diseases | 7 |
hid patients | 7 |
clinical outcome | 7 |
workers without | 7 |
lumbar puncture | 7 |
treatment eff | 7 |
trans mission | 7 |
human disease | 7 |
fatal case | 7 |
new vaccines | 7 |
rotavirus antigen | 7 |
dromedary exposure | 7 |
blood vessels | 7 |
infected people | 7 |
throat swabs | 7 |
physical distancing | 7 |
nervous system | 7 |
highly infectious | 7 |
respiratory droplets | 7 |
health system | 7 |
human betacoronavirus | 7 |
seasonal coronaviruses | 7 |
emerging human | 7 |
genome sequencing | 7 |
rapid antigen | 7 |
epidemiological investigation | 7 |
cystic fi | 7 |
simplex virus | 7 |
confi rm | 7 |
asymptomatic sars | 7 |
suffi cient | 7 |
level isolation | 7 |
low pathogenic | 7 |
virus replication | 7 |
early stages | 7 |
health emergency | 7 |
surveillance systems | 7 |
abu dhabi | 7 |
coronavirus infections | 7 |
exposed workers | 7 |
diff er | 7 |
sars transmission | 7 |
cases detected | 7 |
symptom alleviation | 7 |
betacoronavirus lineage | 7 |
inactivated influenza | 7 |
lancet infectious | 7 |
marrow transplantation | 6 |
live attenuated | 6 |
specific antibody | 6 |
study shows | 6 |
molecular tests | 6 |
health services | 6 |
unpasteurised camel | 6 |
disease surveillance | 6 |
increased susceptibility | 6 |
two human | 6 |
invasive aspergillosis | 6 |
cruise ships | 6 |
median viral | 6 |
pulmonary tuberculosis | 6 |
multivariate analysis | 6 |
yellow fever | 6 |
testing positive | 6 |
vaccine production | 6 |
relevant articles | 6 |
new jersey | 6 |
invasive procedures | 6 |
antimicrobial drugs | 6 |
colleagues described | 6 |
immune individuals | 6 |
viral diseases | 6 |
rna helicase | 6 |
descriptive study | 6 |
insuffi cient | 6 |
glass opacities | 6 |
asp gly | 6 |
human serum | 6 |
immunocompromised patients | 6 |
vitro studies | 6 |
early diagnosis | 6 |
human toll | 6 |
enterovirus detection | 6 |
treatment groups | 6 |
quarantine period | 6 |
gene expression | 6 |
clinical findings | 6 |
exact test | 6 |
population stratifi | 6 |
phase clinical | 6 |
fi gures | 6 |
might provide | 6 |
clinical outcomes | 6 |
million people | 6 |
chest radiograph | 6 |
virus shedding | 6 |
bacterial pathogens | 6 |
serum sample | 6 |
pregnant women | 6 |
lower lobe | 6 |
respiratory samples | 6 |
biological weapons | 6 |
antimicrobial resistance | 6 |
biosafety level | 6 |
chain reaction | 6 |
health policy | 6 |
mycobacterium tuberculosis | 6 |
past decade | 6 |
hospital outbreak | 6 |
critical care | 6 |
common ancestor | 6 |
stratifi cation | 6 |
contract number | 6 |
human respiratory | 6 |
mg every | 6 |
polymerase chain | 6 |
interferon alfacon | 6 |
rmed cases | 6 |
isolation room | 6 |
infected pneumonia | 6 |
older age | 6 |
rapid spread | 6 |
neutralisation assays | 6 |
parainfl uenza | 6 |
also reported | 6 |
directed therapies | 6 |
np igg | 6 |
member states | 6 |
association studies | 6 |
mean time | 6 |
study also | 6 |
mg twice | 6 |
cov genome | 6 |
national institute | 6 |
interstitial pneumonia | 6 |
literature review | 6 |
eff orts | 6 |
epidemiological characteristics | 6 |
us food | 6 |
phase trial | 6 |
intravenous peramivir | 6 |
load profile | 6 |
animal health | 6 |
genes encoding | 6 |
health diplomacy | 6 |
increased virulence | 6 |
severely ill | 6 |
mg health | 6 |
acute upper | 6 |
occurring epidemics | 6 |
chest ct | 6 |
locally transmitted | 6 |
protease inhibitors | 6 |
stem cell | 6 |
risk factor | 6 |
high levels | 6 |
ice detention | 6 |
issues related | 6 |
bacterial infections | 6 |
international spread | 6 |
preventive treatment | 6 |
cause disease | 6 |
causative agent | 6 |
clinical type | 6 |
available data | 6 |
viral titres | 6 |
cell positivity | 6 |
acid receptor | 6 |
antibody concentrations | 6 |
type i | 6 |
internal proteins | 6 |
factors associated | 6 |
haemagglutinin cleavage | 6 |
clinical progression | 6 |
reproductive number | 6 |
pcr tests | 6 |
categorical variables | 6 |
protein microarray | 6 |
systemic corticosteroids | 6 |
international concern | 6 |
previously reported | 6 |
cov qatar | 6 |
old man | 6 |
enrolled participants | 6 |
primary endpoint | 6 |
young infants | 6 |
negative pressure | 6 |
randomly assigned | 6 |
aged days | 6 |
stool samples | 6 |
well tolerated | 6 |
surveillance data | 6 |
zoonotic disease | 6 |
infected health | 6 |
case definition | 6 |
time course | 6 |
case detection | 6 |
antiviral resistance | 6 |
positive results | 6 |
every year | 6 |
two cases | 6 |
oral administration | 6 |
microbial products | 6 |
eff ectively | 6 |
specifi cally | 6 |
radiology department | 6 |
humoral immune | 6 |
epidemiological features | 6 |
mononuclear cells | 6 |
inactivated vaccine | 6 |
serology testing | 6 |
epidemiological investigations | 5 |
common symptom | 5 |
creatine kinase | 5 |
bovine serum | 5 |
adaptive immune | 5 |
renal failure | 5 |
host cell | 5 |
specific cd | 5 |
laboratory findings | 5 |
health policies | 5 |
initial assessment | 5 |
serology test | 5 |
children younger | 5 |
participants enrolled | 5 |
covid pneumonia | 5 |
monoclonal antibody | 5 |
drinking unpasteurised | 5 |
early phase | 5 |
winter months | 5 |
blood specimens | 5 |
serum specimens | 5 |
fl uorescent | 5 |
results suggest | 5 |
community quarantine | 5 |
reduction neutralisation | 5 |
viral sequences | 5 |
age years | 5 |
speech droplets | 5 |
mycophenolic acid | 5 |
fetal bovine | 5 |
infectious day | 5 |
diagnostic testing | 5 |
rotavirus vaccine | 5 |
individual quarantine | 5 |
associated sars | 5 |
entry screening | 5 |
odds ratio | 5 |
occupational exposure | 5 |
interferon beta | 5 |
lung pathology | 5 |
antimalarial activity | 5 |
international legislation | 5 |
glu lys | 5 |
mg medicine | 5 |
immune genes | 5 |
therapeutic options | 5 |
health management | 5 |
ectodermal dysplasia | 5 |
zoonotic mers | 5 |
african ebola | 5 |
findings suggest | 5 |
military personnel | 5 |
receptor gene | 5 |
commercially available | 5 |
early symptom | 5 |
important part | 5 |
transplant recipients | 5 |
time pcr | 5 |
neutralisation test | 5 |
large numbers | 5 |
kumbh mela | 5 |
specific antibodies | 5 |
protective effect | 5 |
infected contacts | 5 |
antiviral eff | 5 |
presenting symptoms | 5 |
clinical signs | 5 |
supportive care | 5 |
ns protein | 5 |
received ribavirin | 5 |
contact investigation | 5 |
dose oseltamivir | 5 |
three groups | 5 |
pfi zer | 5 |
inflammatory infiltrate | 5 |
transducing molecules | 5 |
took place | 5 |
policy makers | 5 |
case history | 5 |
rotavirus diarrhoea | 5 |
acquired infections | 5 |
cov spike | 5 |
csf samples | 5 |
symptom severity | 5 |
coronavirus spike | 5 |
valley fever | 5 |
eff ector | 5 |
early warning | 5 |
naive populations | 5 |
civil aviation | 5 |
antibody test | 5 |
imported cases | 5 |
pneumonic plague | 5 |
northern italy | 5 |
influenza infection | 5 |
avascular necrosis | 5 |
mean age | 5 |
creatinine clearance | 5 |
linkage disequilibrium | 5 |
individuals aged | 5 |
secondary infections | 5 |
also needed | 5 |
many countries | 5 |
molecules targeting | 5 |
many patients | 5 |
signalling pathways | 5 |
rmed mers | 5 |
human monoclonal | 5 |
surveillance system | 5 |
pandemic response | 5 |
infectious period | 5 |
internal genes | 5 |
nasal airflow | 5 |
secondary metabolites | 5 |
another study | 5 |
dose group | 5 |
acid homology | 5 |
linked immunosorbent | 5 |
aseptic meningitis | 5 |
virus concentrations | 5 |
poultry farms | 5 |
well plates | 5 |
serological study | 5 |
viral culture | 5 |
rapid response | 5 |
home communities | 5 |
respiratory diseases | 5 |
diseases caused | 5 |
galactose linkages | 5 |
global infectious | 5 |
francisella tularensis | 5 |
receptor polymorphisms | 5 |
medical city | 5 |
cases identified | 5 |
serological investigation | 5 |
survival benefi | 5 |
united kingdom | 5 |
rift valley | 5 |
disease alert | 5 |
inhalation anthrax | 5 |
symptomatic health | 5 |
study clinical | 5 |
crowd control | 5 |
emerging pandemic | 5 |
accessory proteins | 5 |
general public | 5 |
pneumocyte hyperplasia | 5 |
clinical applications | 5 |
sars pneumonia | 5 |
olympic games | 5 |
many people | 5 |
clinical manifestations | 5 |
higher proportion | 5 |
detection limit | 5 |
nasopharyngeal viral | 5 |
new zealand | 5 |
spike gene | 5 |
univariate analysis | 5 |
poorly immunogenic | 5 |
probable sars | 5 |
laboratory confi | 5 |
defi nitions | 5 |
ongoing covid | 5 |
clinical study | 5 |
human population | 5 |
mecca pilgrimage | 5 |
written informed | 5 |
disease progression | 5 |
associated infection | 5 |
median age | 5 |
immunofl uorescence | 5 |
potential pandemic | 5 |
preliminary report | 5 |
bacterial infection | 5 |
pcr test | 5 |
classifi cation | 5 |
mild illness | 5 |
pcr assays | 5 |
candida albicans | 5 |
ct scan | 5 |
hubei province | 5 |
blood count | 5 |
rna copies | 5 |
policy decisions | 5 |
bronchoalveolar lavage | 5 |
humoral immunity | 5 |
eastern china | 5 |
pneu monia | 5 |
cov specific | 5 |
adults might | 5 |
real time | 5 |
mg kg | 5 |
pharyngeal congestion | 5 |
neutralisation tests | 5 |
global alert | 5 |
european network | 5 |
observational studies | 5 |
reported worldwide | 5 |
gene polymorphisms | 5 |
neutralising activity | 5 |
infection risks | 5 |
will probably | 5 |
immunity passport | 5 |
cytotoxic effects | 5 |
febrile illness | 5 |
rna concentrations | 5 |
neutrophil count | 5 |
emerging viral | 5 |
taking place | 5 |
physical examination | 5 |
lung tissue | 5 |
time reverse | 5 |
significantly lower | 5 |
nitric oxide | 5 |
qatar orf | 5 |
occupational health | 5 |
new drug | 5 |
allogeneic stem | 5 |
existing drugs | 5 |
infectious gastroenteritis | 5 |
viral genome | 5 |
supportive therapy | 5 |
inhibitory activity | 5 |
asymptomatic individuals | 5 |
systemic symptoms | 5 |
environmental samples | 5 |
interferon alpha | 5 |
continuous variables | 5 |
blood sample | 5 |
meningococcal disease | 5 |
benefi ts | 5 |
baseline characteristics | 5 |
first clinical | 5 |
virus subtypes | 5 |
viral diagnosis | 5 |
clinical diagnosis | 5 |
runny nose | 5 |
prompt isolation | 5 |
virus type | 5 |
requiring admission | 5 |
clinical severity | 5 |
day survival | 5 |
control group | 5 |
bioterrorist attack | 5 |
studies showed | 5 |
rapid detection | 5 |
spike glycoprotein | 5 |
establish whether | 5 |
proinflammatory cytokines | 5 |
hand hygiene | 5 |
standard precautions | 5 |
security risks | 5 |
oral ribavirin | 5 |
phase response | 5 |
peritoneal dialysis | 5 |
vero cells | 5 |
study showed | 5 |
live virus | 5 |
related viruses | 5 |
immune status | 5 |
respiratory viral | 5 |
staff working | 5 |
extensively drug | 5 |
phylogenetic analyses | 5 |
mean infectious | 5 |
community spread | 5 |
genome sequences | 5 |
primary case | 5 |
classifi ed | 5 |
acute disease | 5 |
airborne transmission | 5 |
practice guidelines | 5 |
per day | 4 |
fatality rate | 4 |
dualenergy ct | 4 |
viral infectivity | 4 |
two negative | 4 |
biosecurity measures | 4 |
rbd igm | 4 |
term consequences | 4 |
plasma therapy | 4 |
high rates | 4 |
asymptomatic lung | 4 |
illness caused | 4 |
large proportion | 4 |
paediatric population | 4 |
antibiotic treatment | 4 |
neuraminidase subtypes | 4 |
blood mononuclear | 4 |
new class | 4 |
low risk | 4 |
lung opacities | 4 |
remain asymptomatic | 4 |
exit screening | 4 |
zhejiang province | 4 |
million cases | 4 |
symptoms associated | 4 |
chest radiography | 4 |
many marine | 4 |
global research | 4 |
immunodiagnostic tests | 4 |
nasopharyngeal specimens | 4 |
novel avian | 4 |
group aged | 4 |
high rate | 4 |
virus isolated | 4 |
animal exposures | 4 |
national health | 4 |
mg dose | 4 |
class i | 4 |
np igm | 4 |
molecular diagnosis | 4 |
will still | 4 |
lessons learned | 4 |
widespread use | 4 |
west indian | 4 |
every participant | 4 |
integral part | 4 |
potential risk | 4 |
two diff | 4 |
medical services | 4 |
paired samples | 4 |
sickle cell | 4 |
infectious passengers | 4 |
modern hajj | 4 |
genome sequence | 4 |
animal reservoirs | 4 |
abdominal cramping | 4 |
host defences | 4 |
cell cultures | 4 |
interferon therapy | 4 |
received lopinavir | 4 |
randomised clinical | 4 |
vivo efficacy | 4 |
reduced mortality | 4 |
censored data | 4 |
response plan | 4 |
laboratory data | 4 |
primary care | 4 |
uorescence assay | 4 |
upper airways | 4 |
emergency management | 4 |
virus isolates | 4 |
innate immunogenetics | 4 |
vs placebo | 4 |
first days | 4 |
malaria transmission | 4 |
statistical analysis | 4 |
prolonged detection | 4 |
sars patients | 4 |
southeast asia | 4 |
done using | 4 |
appendix pp | 4 |
aff ects | 4 |
moderate clinical | 4 |
internal nucleoprotein | 4 |
immunological response | 4 |
planning mgs | 4 |
virus might | 4 |
coronavirus diseases | 4 |
clinical data | 4 |
infection rates | 4 |
spectrum antibiotics | 4 |
neutralisation assay | 4 |
support rapid | 4 |
health intervention | 4 |
highly variable | 4 |
case management | 4 |
positive predictive | 4 |
analysed data | 4 |
malaria burden | 4 |
endotracheal intubation | 4 |
patients enrolled | 4 |
acute lung | 4 |
retrospective case | 4 |
antimicrobial activity | 4 |
confirmed infection | 4 |
syndrome clinical | 4 |
perfusion abnormalities | 4 |
affi nity | 4 |
water supply | 4 |
antibody kinetics | 4 |
river delta | 4 |
available mers | 4 |
fl uconazole | 4 |
higher rates | 4 |
small intestine | 4 |
symptoms will | 4 |
posterior oro | 4 |
uenza infection | 4 |
plasmodium falciparum | 4 |
assay titres | 4 |
intravenous zanamivir | 4 |
lung disease | 4 |
treating infl | 4 |
seriously ill | 4 |
klinikum schwabing | 4 |
erent types | 4 |
mgs include | 4 |
genetic characterization | 4 |
inhibitory eff | 4 |
common colds | 4 |
laboratory workers | 4 |
malaria intervention | 4 |
fusion inhibitors | 4 |
resistant strains | 4 |
fever viruses | 4 |
defi ciency | 4 |
new york | 4 |
nearly half | 4 |
noncommunicable diseases | 4 |
screening measures | 4 |
igg reactivity | 4 |
epidemic areas | 4 |
yet unknown | 4 |
pcr results | 4 |
zika virus | 4 |
viruses generally | 4 |
ethics committee | 4 |
many years | 4 |
animal products | 4 |
past years | 4 |
first years | 4 |
small proportion | 4 |
randomised trial | 4 |
postexposure prophylaxis | 4 |
reverse transcription | 4 |
sequences obtained | 4 |
virological analysis | 4 |
first case | 4 |
secretory iga | 4 |
symptom associated | 4 |
containment measures | 4 |
ineff ective | 4 |
uenza pandemic | 4 |
severe sepsis | 4 |
positive control | 4 |
two groups | 4 |
remains unclear | 4 |
sultan military | 4 |
enhanced surveillance | 4 |
publicly available | 4 |
well documented | 4 |
one animal | 4 |
resistant disease | 4 |
inhibits replication | 4 |
protective antigen | 4 |
missing link | 4 |
marine fungus | 4 |
negative control | 4 |
control efforts | 4 |
vaccine trials | 4 |
lung infection | 4 |
chronic diarrhoea | 4 |
developing symptoms | 4 |
nerve endings | 4 |
international civil | 4 |
possible animal | 4 |
high titre | 4 |
romark laboratories | 4 |
isolation ward | 4 |
per dose | 4 |
human populations | 4 |
uenza antibody | 4 |
income countries | 4 |
european member | 4 |
participants treated | 4 |
virus via | 4 |
asymptomatic cases | 4 |
epidemic area | 4 |
urti symptoms | 4 |
thr ala | 4 |
patients undergoing | 4 |
surveillance group | 4 |
statistically significant | 4 |
spanish influenza | 4 |
improved survival | 4 |
igg od | 4 |
pulmonary aspergillosis | 4 |
one individual | 4 |
signifi cance | 4 |
coronavirus outbreak | 4 |
transmitted cases | 4 |
medical records | 4 |
serological studies | 4 |
tract samples | 4 |
poultry workers | 4 |
dangerous pathogens | 4 |
samples obtained | 4 |
epidemiological information | 4 |
severe covid | 4 |
confirmed case | 4 |
scientific evidence | 4 |
may cause | 4 |
hospitalised patients | 4 |
two decades | 4 |
previous studies | 4 |
low incidence | 4 |
fi lm | 4 |
intentional outbreaks | 4 |
diffi culties | 4 |
much milder | 4 |
human viruses | 4 |
substantial proportion | 4 |
higher antibody | 4 |
multiple myeloma | 4 |
older adults | 4 |
vaccine seed | 4 |
virological testing | 4 |
antiviral drug | 4 |
negatively associated | 4 |
previously published | 4 |
nucleotide polymorphisms | 4 |
detailed case | 4 |
military medical | 4 |
us military | 4 |
infection will | 4 |
travel history | 4 |
inflammatory response | 4 |
cantly diff | 4 |
people might | 4 |
proliferative phases | 4 |
sarscoronavirus replication | 4 |
active case | 4 |
cell response | 4 |
consensus statement | 4 |
binding specificity | 4 |
political will | 4 |
serological assay | 4 |
maximum likelihood | 4 |
much higher | 4 |
major outbreak | 4 |
virus rna | 4 |
low concentrations | 4 |
treatment outcomes | 4 |
civil liberties | 4 |
chinese center | 4 |
west africa | 4 |
nal responsibility | 4 |
antigen reactivity | 4 |
previous study | 4 |
mainland china | 4 |
rna polymerase | 4 |
aviation organization | 4 |
coronavirus antibodies | 4 |
cantly lower | 4 |
potent inhibitory | 4 |
including animal | 4 |
exposure history | 4 |
control strategies | 4 |
day quarantine | 4 |
heightened surveillance | 4 |
hospital stay | 4 |
health experts | 4 |
several studies | 4 |
confirmed mers | 4 |
enhance immunogenicity | 4 |
also shown | 4 |
highly sensitive | 4 |
mortem examination | 4 |
rapid diagnostic | 4 |
response program | 4 |
serological data | 4 |
parainfluenza virus | 4 |
increased perfusion | 4 |
cov infected | 4 |
ective treatment | 4 |
group compared | 4 |
crucial role | 4 |
absolute neutrophil | 4 |
african green | 4 |
dipeptidyl peptidase | 4 |
patients might | 4 |
antimalarial drug | 4 |
english language | 4 |
avian origin | 4 |
skeletal muscle | 4 |
igg antibody | 4 |
od values | 4 |
detention facilities | 4 |
infection risk | 4 |
pulsed steroids | 4 |
less severe | 4 |
offi ce | 4 |
nose swabs | 4 |
single dose | 4 |
behavioural science | 4 |
emergency room | 4 |
cough may | 4 |
nasal cycle | 4 |
highly contagious | 4 |
research directions | 4 |
acute diarrhoea | 4 |
pandemic potential | 4 |
cells per | 4 |
pcr assay | 4 |
adverse eff | 4 |
also shows | 4 |
camel populations | 4 |
virus expressing | 4 |
nine individuals | 4 |
disease associated | 4 |
patient care | 4 |
sick contact | 4 |
study group | 4 |
sneeze centre | 4 |
zoonotic infection | 4 |
subcutaneous pegylated | 4 |
chest radiographs | 4 |
short period | 4 |
convalescent cases | 4 |
rapid viral | 4 |
virus challenge | 4 |
low pathogenicity | 4 |
cov sequences | 4 |
colleagues showed | 4 |
influenza strains | 4 |
patients presenting | 4 |
reduce exposure | 4 |
disease course | 4 |
oligomerisation domain | 4 |
otherwise healthy | 4 |
although substantial | 4 |
management strategies | 4 |
us health | 4 |
vaccinated animals | 4 |
bioterrorist agents | 4 |
borne diseases | 4 |
infected children | 4 |
several factors | 4 |
care systems | 4 |
time needed | 4 |
randomized controlled | 4 |
serology assay | 4 |
tlr detects | 4 |
nosocomial infection | 4 |
like viruses | 4 |
health systems | 4 |
international air | 4 |
controlled trials | 4 |
best practices | 4 |
bat coronavirus | 4 |
genetic analysis | 4 |
authors contributed | 4 |
decision makers | 4 |
initial viral | 4 |
temporal viral | 4 |
gene segments | 4 |
enterovirus infections | 4 |
intentional contamination | 4 |
allergic bronchopulmonary | 4 |
health commission | 4 |
anthrax vaccination | 4 |
authors declare | 4 |
past two | 4 |
clinical development | 4 |
health response | 4 |
escherichia coli | 4 |
also found | 4 |
inanimate surfaces | 4 |
rna interference | 4 |
optimal ppe | 4 |
broad range | 4 |
temporal profiles | 4 |
molecular biology | 4 |
molecular clock | 4 |
saturating reactivity | 4 |
microneutralisation assay | 4 |
laboratory safety | 4 |
cd ra | 4 |
quantitative rt | 4 |
whether sars | 4 |
clinical samples | 4 |
predictive value | 4 |
cold viruses | 4 |
symptom relief | 4 |
intermittent preventive | 4 |
profi les | 4 |
adults admitted | 4 |
control study | 4 |
mol kg | 4 |
viral titre | 4 |
study participants | 4 |
health surveillance | 4 |
rotavirus antibodies | 4 |
among children | 4 |
small sample | 4 |
risk groups | 4 |
many cases | 4 |
dry cough | 4 |
will depend | 4 |
care setting | 4 |
medical history | 4 |
like diseases | 4 |
effective means | 4 |
whole blood | 4 |
fl exible | 4 |
pandemic strains | 4 |
enterovirus genotypes | 4 |
select agents | 4 |
differential diagnosis | 4 |
health workers | 4 |
ethnic groups | 4 |
drug resistance | 4 |
haemorrhagic fevers | 4 |
acute covid | 4 |
vice versa | 4 |
authors reviewed | 4 |
early clinical | 4 |
widely used | 4 |
antibody detection | 4 |
one sample | 4 |
healthcare facilities | 4 |
control groups | 4 |
cov rna | 4 |
become available | 4 |
cov case | 4 |
within weeks | 4 |
novel mechanisms | 4 |
per person | 4 |
extracorporeal membrane | 4 |
central nervous | 4 |
viruses causing | 4 |
severe pandemic | 4 |
participants aged | 4 |
prince sultan | 4 |
staphylococcus aureus | 4 |
southern china | 4 |
pcr result | 4 |
rotavirus particles | 4 |
us immigration | 4 |
red sea | 4 |
mhc class | 4 |
antimalarial drugs | 4 |
viral respiratory | 4 |
spanish camels | 4 |
whole virus | 4 |
commercial air | 4 |
clinical experience | 4 |
associated transmission | 3 |
treatment benefi | 3 |
oral fluid | 3 |
outbreak investigation | 3 |
traffi cking | 3 |
humoral response | 3 |
acinetobacter baumannii | 3 |
severe infections | 3 |
two samples | 3 |
regression analysis | 3 |
health implications | 3 |
pharmacologically tested | 3 |
norwalk virus | 3 |
based reverse | 3 |
immunodefi ciency | 3 |
patient cohort | 3 |
search term | 3 |
detectable antibody | 3 |
hospital authority | 3 |
infl ammasome | 3 |
protective efficacy | 3 |
screening test | 3 |
jaspis sp | 3 |
tract symptoms | 3 |
science foundation | 3 |
laboratory diagnosis | 3 |
urgent priority | 3 |
drug leads | 3 |
two cities | 3 |
rotavirus diarrhea | 3 |
white blood | 3 |
invasive pulmonary | 3 |
rna detected | 3 |
mammalian adaptation | 3 |
infections clinical | 3 |
cov genomes | 3 |
igg assay | 3 |
pseudopterogorgia elisabethae | 3 |
coronavirus receptor | 3 |
university hospital | 3 |
potential candidates | 3 |
blood donors | 3 |
protective gear | 3 |
many similarities | 3 |
control procedures | 3 |
disease enhancement | 3 |
mature enterocytes | 3 |
outbreak response | 3 |
ribavirin treatment | 3 |
animal disease | 3 |
appropriately designed | 3 |
patients remained | 3 |
infants aged | 3 |
gastroenteritis among | 3 |
duck hokkaido | 3 |
scientific expertise | 3 |
infectious waste | 3 |
infections might | 3 |
available evidence | 3 |
research council | 3 |
patients treated | 3 |
viral pathogens | 3 |
symptomatic cases | 3 |
domestic poultry | 3 |
cov antibody | 3 |
immunosorbent assay | 3 |
converting enzyme | 3 |
host proteins | 3 |
single radial | 3 |
develop resistance | 3 |
targeting viral | 3 |
viral meningitis | 3 |
health intelligence | 3 |
diarrhoea among | 3 |
potential risks | 3 |
respiratory muscles | 3 |
infecting human | 3 |
wide spectrum | 3 |
specimens per | 3 |
pulmonary fungal | 3 |
poultry vaccination | 3 |
improves outcome | 3 |
without fever | 3 |
human novel | 3 |
southern australian | 3 |
careful monitoring | 3 |
tetramic acid | 3 |
new anti | 3 |
existing inequalities | 3 |
response measures | 3 |
serial samples | 3 |
vitro methods | 3 |
sensitivity analyses | 3 |
laboratory worker | 3 |
dromedary camel | 3 |
prevention strategies | 3 |
endotracheal aspirate | 3 |
reliable diagnostic | 3 |
pathogenic strains | 3 |
fold increase | 3 |
less common | 3 |
posterior oropharynx | 3 |
throat irritation | 3 |
many different | 3 |
reproduction number | 3 |
among people | 3 |
testing capacity | 3 |
host immunity | 3 |
serological methods | 3 |
sequence analysis | 3 |
uenza drug | 3 |
less frequent | 3 |
highly prevalent | 3 |
asymptomatic infections | 3 |
segmented genome | 3 |
two bactrian | 3 |
forming units | 3 |
south africa | 3 |
particulate air | 3 |
interpandemic influenza | 3 |
giovanni xxiii | 3 |
effective vaccines | 3 |
affected countries | 3 |
german hospital | 3 |
health service | 3 |
high mortality | 3 |
activity relation | 3 |
infected poultry | 3 |
offi cial | 3 |
rmed infection | 3 |
com bination | 3 |
defi ne | 3 |
vary greatly | 3 |
modelling study | 3 |
several limitations | 3 |
alexa fluor | 3 |
healthcare worker | 3 |
elderly people | 3 |
inhaled zanamivir | 3 |
cohort studies | 3 |
virological assessment | 3 |
initiated intentionally | 3 |
potentially infectious | 3 |
international collaboration | 3 |
pulmonary emboli | 3 |
may occur | 3 |
right lower | 3 |
emerging infections | 3 |
mean serial | 3 |
respond rapidly | 3 |
uenza season | 3 |
potentially infected | 3 |
several observational | 3 |
nucleic acid | 3 |
cavernous tissue | 3 |
king abdulaziz | 3 |
arterial vessels | 3 |
ct features | 3 |
environmental factors | 3 |
mice infected | 3 |
events associated | 3 |
free movement | 3 |
cov might | 3 |
identify possible | 3 |
including sars | 3 |
affected areas | 3 |
poor infrastructure | 3 |
capillary congestion | 3 |
amplifi ed | 3 |
extended periods | 3 |
pulmonary vascular | 3 |
important cause | 3 |
common respiratory | 3 |
nucleotide polymorphism | 3 |
japanese pipistrelle | 3 |
positive cells | 3 |
linked receptors | 3 |
throughput genotyping | 3 |
public education | 3 |
public places | 3 |
natural disasters | 3 |
evidence supporting | 3 |
vitro inhibitory | 3 |
ten passengers | 3 |
vagus nerve | 3 |
become less | 3 |
trim alpha | 3 |
large cohort | 3 |
licensing criteria | 3 |
colleagues also | 3 |
proportional hazards | 3 |
although one | 3 |
novel middle | 3 |
response epidemiology | 3 |
recent advances | 3 |
may require | 3 |
following sars | 3 |
coronavirus vaccine | 3 |
individuals infected | 3 |
vaccination might | 3 |
mg nitazoxanide | 3 |
overnight poultry | 3 |
interpandemic periods | 3 |
important components | 3 |
confirmed sars | 3 |
accessing testing | 3 |
second dose | 3 |
testing might | 3 |
inhibitory concentration | 3 |
species barrier | 3 |
host factors | 3 |
transplant patients | 3 |
smallpox virus | 3 |
unrelated cases | 3 |
pandemic preparedness | 3 |
terms covid | 3 |
projects emperie | 3 |
mers survivors | 3 |
chronic medical | 3 |
pandemic planning | 3 |
immunisation strategies | 3 |
geographic location | 3 |
involving multiple | 3 |
prevent nosocomial | 3 |
become symptomatic | 3 |
cells targeting | 3 |
protein rbd | 3 |
endemic human | 3 |
indian subcontinent | 3 |
conclude whether | 3 |
nasopharyngeal aspirate | 3 |
may explain | 3 |
healthy controls | 3 |
pcr positive | 3 |
common adverse | 3 |
phase randomised | 3 |
viruses may | 3 |
paediatric wards | 3 |
first weeks | 3 |
plasma concentrations | 3 |
linked sialic | 3 |
surveillance reduced | 3 |
organising pneumonia | 3 |
coronavirus hku | 3 |
basic science | 3 |
adjunct therapies | 3 |
clinically achievable | 3 |
frontline health | 3 |
will strengthen | 3 |
respiratory tracts | 3 |
natural killer | 3 |
green monkeys | 3 |
host species | 3 |
host defence | 3 |
younger adults | 3 |
among health | 3 |
molecular assays | 3 |
small case | 3 |
reduced risk | 3 |
committee meeting | 3 |
host recognition | 3 |
transport medium | 3 |
including deaths | 3 |
countries must | 3 |
drug discovery | 3 |
legitimate research | 3 |
infection induces | 3 |
several countries | 3 |
genotyping techniques | 3 |
sensory nerves | 3 |
workers infected | 3 |
among household | 3 |
salivary glands | 3 |
socioeconomic status | 3 |
fibrotic phase | 3 |
selection criteria | 3 |
transmission chain | 3 |
mg loading | 3 |
various treatments | 3 |
substantial rise | 3 |
higher among | 3 |
emerging disease | 3 |
traditional public | 3 |
connecting clusters | 3 |
endemic disease | 3 |
growing number | 3 |
microbiology laboratories | 3 |
swab specimens | 3 |
bodily fluids | 3 |
neutralising serum | 3 |
missing data | 3 |
haemagglutinin vaccines | 3 |
designed randomised | 3 |
symptomatic individuals | 3 |
epidemiology team | 3 |
cough etiquette | 3 |
smallpox vaccine | 3 |
fungal pathogens | 3 |
documented viral | 3 |
febrile patients | 3 |
transmission chains | 3 |
causes severe | 3 |
two loci | 3 |
facilities sars | 3 |
dose schedule | 3 |
observed reproductive | 3 |
gambieric acids | 3 |
highly eff | 3 |
omani camels | 3 |
rst human | 3 |
antibody level | 3 |
ed reports | 3 |
ace receptor | 3 |
patients develop | 3 |
important role | 3 |
botulinum toxoid | 3 |
facilitate early | 3 |
queen mary | 3 |
watery eyes | 3 |
luigi sacco | 3 |
product vaccines | 3 |
biological threat | 3 |
disease outcome | 3 |
antibodies reactive | 3 |
gain access | 3 |
muramyl dipeptide | 3 |
amplifi cation | 3 |
immune protection | 3 |
pneumonia emergency | 3 |
zoonotic coronaviruses | 3 |
data suggest | 3 |
five patients | 3 |
attenuated parainfluenza | 3 |
new agents | 3 |
islamic world | 3 |
veterinary purposes | 3 |
million pilgrims | 3 |
sample collection | 3 |
high attack | 3 |
quantitative virus | 3 |
suspected infection | 3 |
direct transmission | 3 |
viruses infect | 3 |
might require | 3 |
vitro antiviral | 3 |
entero virus | 3 |
pneumocystis jirovecii | 3 |
medical research | 3 |
attenuated cold | 3 |
sars vaccines | 3 |
venous sinuses | 3 |
associated molecular | 3 |
without dromedary | 3 |
global concern | 3 |
tissue culture | 3 |
made available | 3 |
primary analysis | 3 |
host susceptibility | 3 |
undetectable viral | 3 |
pathogen transmission | 3 |
current study | 3 |
blood monocytes | 3 |
ctl responses | 3 |
translational level | 3 |
effector memory | 3 |
mean duration | 3 |
people living | 3 |
sporadic cases | 3 |
binding oligomerisation | 3 |
type interferons | 3 |
upper airway | 3 |
starting dilution | 3 |
proposed research | 3 |
significantly higher | 3 |
review anti | 3 |
infections across | 3 |
electron microscope | 3 |
higher risk | 3 |
intranasal administration | 3 |
matrix protein | 3 |
corona virus | 3 |
human services | 3 |
lower prevalence | 3 |
adult inpatients | 3 |
across africa | 3 |
bactrian camels | 3 |
sacco hospital | 3 |
potential impact | 3 |
fl uorescence | 3 |
measures will | 3 |
will always | 3 |
whole genome | 3 |
first draft | 3 |
recent years | 3 |
hliu high | 3 |
quantifi ed | 3 |
pulmonary pathology | 3 |
autopsy studies | 3 |
participants infected | 3 |
muscle aches | 3 |
virion sars | 3 |
inactivated whole | 3 |
exclusion criteria | 3 |
detection tests | 3 |
isolation unit | 3 |
organ failure | 3 |
endemic regions | 3 |
used clinically | 3 |
mural fibrosis | 3 |
membrane oxygenation | 3 |
uenza pneumonia | 3 |
papa giovanni | 3 |
adult gastroenteritis | 3 |
recombinant baculovirus | 3 |
one human | 3 |
received several | 3 |
gastroenteritis due | 3 |
pharyngeal swabs | 3 |
geographically structured | 3 |
later symptoms | 3 |
viral transport | 3 |
convalescent phases | 3 |
timely access | 3 |
ct imaging | 3 |
nasal secretions | 3 |
long term | 3 |
zealand sponge | 3 |
bacterial peptidoglycan | 3 |
endosomal compartment | 3 |
least two | 3 |
vaccine strain | 3 |
tlr gene | 3 |
finding suggests | 3 |
rapid assessment | 3 |
mental health | 3 |
life conditions | 3 |
acting neuraminidase | 3 |
epidemiological studies | 3 |
hospitalized adults | 3 |
assess potential | 3 |
remained asymptomatic | 3 |
strongly inhibited | 3 |
cancer chemotherapy | 3 |
since december | 3 |
improved understanding | 3 |
cov structural | 3 |
molecular patterns | 3 |
mice model | 3 |
health perspective | 3 |
average number | 3 |
cause harm | 3 |
radiology technicians | 3 |
target cells | 3 |
detect cases | 3 |
therapeutic index | 3 |
community settings | 3 |
serological responses | 3 |
etiologic agent | 3 |
primate model | 3 |
nuclear factor | 3 |
stalk region | 3 |
mild respiratory | 3 |
mortality associated | 3 |
written consent | 3 |
contagious disease | 3 |
sinus pain | 3 |
flight transmission | 3 |
described previously | 3 |
two churches | 3 |
cell line | 3 |
duck mongolia | 3 |
milder disease | 3 |
multiple organ | 3 |
murine model | 3 |
coming months | 3 |
crossreactive immunity | 3 |
type lectins | 3 |
hospitalized children | 3 |
isolation units | 3 |
corresponding authors | 3 |
zoonotic transmission | 3 |
parasitic diseases | 3 |
local transmission | 3 |
passive transfer | 3 |
cantly decreased | 3 |
attenuated viruses | 3 |
strict enforcement | 3 |
provide protection | 3 |
reverse genetic | 3 |
less effective | 3 |
toxoid vaccine | 3 |
internal viral | 3 |
economic loss | 3 |
destination country | 3 |
test results | 3 |
health risk | 3 |
including three | 3 |
toronto area | 3 |
fl uids | 3 |
bats revealed | 3 |
positive selection | 3 |
oseltamivir treatment | 3 |
false positives | 3 |
outbreak management | 3 |
virus clinical | 3 |
vaccine induced | 3 |
virus transmission | 3 |
genomic study | 3 |
combination therapy | 3 |
will need | 3 |
receptor agonists | 3 |
infection clinical | 3 |
neutralised bovine | 3 |
testing new | 3 |
droplet transmission | 3 |
related illnesses | 3 |
different populations | 3 |
revealed marked | 3 |
body fluids | 3 |
clinical research | 3 |
identifi es | 3 |
including dromedary | 3 |
lower airways | 3 |
international travel | 3 |
exposed populations | 3 |
transmission exists | 3 |
two studies | 3 |
sensitivity analysis | 3 |
haplotype blocks | 3 |
environmental detection | 3 |
rescue therapy | 3 |
molecular epidemiology | 3 |
molecular characterization | 3 |
effl ux | 3 |
china covid | 3 |
primary prevention | 3 |
possible explanation | 3 |
short duration | 3 |
molecular evolution | 3 |
preventive measures | 3 |
clinical implications | 3 |
control policies | 3 |
swab samples | 3 |
mouse model | 3 |
renal dialysis | 3 |
polymerase complex | 3 |
cov neutralisation | 3 |
several approaches | 3 |
advisory committee | 3 |
also associated | 3 |
significantly improved | 3 |
genetically modified | 3 |
inspired oxygen | 3 |
individuals might | 3 |
swab viral | 3 |
avian subtypes | 3 |
inflammatory mediators | 3 |
days among | 3 |
disease burden | 3 |
study drug | 3 |
natural rotavirus | 3 |
people attending | 3 |
intrinsic immunity | 3 |
high frequency | 3 |
deep throat | 3 |
animal species | 3 |
sequence divergence | 3 |
confounding factors | 3 |
pressure ventilation | 3 |
skin blood | 3 |
interstitial lung | 3 |
several days | 3 |
virus infecting | 3 |
destination countries | 3 |
responses might | 3 |
total antibody | 3 |
fl uid | 3 |
barrier nursing | 3 |
biological activities | 3 |
clinical practice | 3 |
take place | 3 |
lowest detection | 3 |
card mutations | 3 |
serum dilution | 3 |
productive cough | 3 |
european study | 3 |
testing showed | 3 |
cacy analyses | 3 |
without comorbidities | 3 |
retrospective study | 3 |
lung damage | 3 |
lung tissues | 3 |
become increasingly | 3 |
familial cluster | 3 |
rising antibody | 3 |
assess ment | 3 |
improve clinical | 3 |
radial haemolysis | 3 |
geriatric hospital | 3 |
poultry outbreaks | 3 |
may result | 3 |
phase ii | 3 |
gene sequences | 3 |
phase i | 3 |
load profi | 3 |
care personnel | 3 |
will provide | 3 |
exposures including | 3 |
high concentrations | 3 |
nasal secretion | 3 |
biological plausibility | 3 |
spike proteins | 3 |
viral kinetics | 3 |
assess eff | 3 |
tuberculosis patients | 3 |
water supplies | 3 |
secondary cases | 3 |
low number | 3 |
oral temperature | 3 |
ammatory response | 3 |
remote areas | 3 |
south american | 3 |
disease patients | 3 |
high igg | 3 |
transmission characteristics | 3 |
novel pathogens | 3 |
infected cases | 3 |
rapid dissemination | 3 |
within families | 3 |
tested marine | 3 |
develop new | 3 |
medical staff | 3 |
versus oseltamivir | 3 |
low levels | 3 |
smallpox vaccines | 3 |
achievable concentrations | 3 |
drugs used | 3 |
covid cases | 3 |
ground glass | 3 |
ct changes | 3 |
chronic pulmonary | 3 |
spp bats | 3 |
standard treatment | 3 |
treated participants | 3 |
acid receptors | 3 |
health effects | 3 |
particles per | 3 |
median incubation | 3 |
many infections | 3 |
acute diarrhea | 3 |
coronavirus indicating | 3 |
risks requires | 3 |
potent antifungal | 3 |
antituberculosis agents | 3 |
genbank accession | 3 |
like virus | 3 |
pneumonia associated | 3 |
ml sec | 3 |
igm antibodies | 3 |
skin temperature | 3 |
three treatment | 3 |
customs enforcement | 3 |
receptor mutations | 3 |
deep sequencing | 3 |
community containment | 3 |
protein receptor | 3 |
many aspects | 3 |
massive crowds | 3 |
loading dose | 3 |
public estate | 3 |
caribbean tunicate | 3 |
principal means | 3 |
vaccinia virus | 3 |
subunit vaccine | 3 |
broad replicative | 3 |
infection treated | 3 |
participating hospitals | 3 |
south america | 3 |
without sars | 3 |
baseline severity | 3 |
within months | 3 |
ex vivo | 3 |
hypoxaemia related | 3 |
suspected hid | 3 |
possible scenarios | 3 |
will continue | 3 |
health status | 3 |
adult contacts | 3 |
us department | 3 |
evidence base | 3 |
respiratory hygiene | 3 |
cd positive | 3 |
small arterial | 3 |
sars cases | 3 |
randomised trials | 3 |
early transmission | 3 |
per patient | 3 |
viral gastroenteritis | 3 |
study middle | 3 |
infectious agents | 3 |
increased binding | 3 |
coronavirus neutralising | 3 |
livestock species | 3 |
type pneumocytes | 3 |
transcription factors | 3 |
oxygen saturation | 3 |
workers might | 3 |
older children | 3 |
cell transplant | 3 |
whereas cd | 3 |
digital surveillance | 3 |
avian flu | 3 |
infection transmission | 3 |
encoding tlrs | 3 |
college students | 3 |
viral transmission | 3 |
environmental contamination | 3 |
peak incidence | 3 |
green light | 3 |
islamic belief | 3 |
level pheic | 3 |
greater toronto | 3 |
vulnerable populations | 3 |
global burden | 3 |
designated sessions | 3 |
igg response | 3 |
uenza molecules | 3 |
viral pneumonia | 3 |
isolation period | 3 |
direct access | 3 |
health interventions | 3 |
treatment strategies | 3 |
particles resembling | 3 |
maintains broad | 3 |
widespread community | 3 |
highly conserved | 3 |
related inversely | 3 |
defi nitive | 3 |
six patients | 3 |
much work | 3 |
aircraft disinsection | 3 |
like symptoms | 3 |
research efforts | 3 |
much lower | 3 |
regression model | 3 |
antifungal metabolites | 3 |
better understanding | 3 |
recovered patients | 3 |
nasal obstruction | 3 |
avian haemagglutinin | 3 |
systematic reviews | 3 |
among healthcare | 3 |
two people | 3 |
pharmaceutical interventions | 3 |
mood changes | 3 |
sex work | 3 |
com infection | 3 |
blood sampling | 3 |
treatment options | 3 |
low sensitivity | 3 |
novel virus | 3 |
respiratory symptom | 3 |
nematocidal activity | 3 |
infections will | 3 |
shows estimates | 3 |
also monitored | 3 |
heterosubtypic immunity | 3 |
laninamivir octanoate | 3 |
treat patients | 3 |
marine leads | 3 |
rotavirus disease | 3 |
three cases | 3 |
body compartments | 3 |
via commercial | 3 |
seasonal influenza | 3 |
vaccine demand | 3 |
case report | 3 |
household members | 3 |
recent infection | 3 |
optical density | 3 |
virus concentration | 3 |
health community | 3 |
neutralizing antibodies | 3 |
asp asn | 3 |
droplet precautions | 3 |
donor compound | 3 |
rapid progress | 3 |
democratic republic | 3 |
genetic reassortment | 3 |
inhibitor laninamivir | 3 |
tripartite motif | 3 |
icu patients | 3 |
cell surface | 3 |
infected mosquitoes | 3 |
vaccine expressing | 3 |
tcid viral | 3 |
human conjunctivitis | 3 |
neutralisation titre | 3 |
household secondary | 3 |
local hospitals | 3 |
enrolled within | 3 |
avoid contact | 3 |
vaccine responses | 3 |
poc testing | 3 |
diagnostic methods | 3 |
chadox ncov | 3 |
animal model | 3 |
antigenic drift | 3 |
vaccine efficacy | 3 |
clear epidemiological | 3 |
virus outbreak | 3 |
defi cient | 3 |
future outbreaks | 3 |
evidence suggests | 3 |
smallpox vaccination | 3 |
containing proteins | 3 |
surface glycoproteins | 3 |
also recruited | 3 |
also noted | 3 |
mortality rates | 3 |
uenza vaccine | 3 |
testing done | 3 |
myocardial enzymes | 3 |
facial muscles | 3 |
increasingly important | 3 |
marine origin | 3 |
acute meningitis | 3 |
temperature screening | 3 |
viral hemagglutinin | 3 |
readily transmitted | 3 |
marine bacteria | 3 |
patient contacts | 3 |
indirect transmission | 3 |
laboratories lc | 3 |
fl agellin | 3 |
analyse data | 3 |
rst case | 3 |
nitazoxanide given | 3 |
shedding live | 3 |
insect cells | 3 |
primed populations | 3 |
uncomplicated influenza | 3 |
causative pathogen | 3 |
local health | 3 |
arg lys | 3 |
term outcomes | 3 |
therapeutic interventions | 3 |
research foundation | 3 |
modifi ed | 3 |
gathering medicine | 3 |
fusion protein | 3 |
clinically significant | 3 |
hospital settings | 3 |
immune cells | 3 |
higher viral | 3 |
blood cell | 3 |
clinically assessed | 3 |
three different | 3 |
infectious pathogens | 3 |
viral proteins | 3 |
replicative capability | 3 |
increasing numbers | 3 |
immunogenetic studies | 3 |
emerging pathogens | 3 |
vaccine antigen | 3 |
referral hospital | 3 |
three hospitals | 3 |
indicating person | 3 |
immunosuppressive therapy | 3 |
term sequelae | 3 |
heptad repeat | 3 |
dual purpose | 3 |
commonly associated | 3 |
bedside radiography | 3 |
large outbreak | 3 |
bronchopulmonary aspergillosis | 3 |
titres varying | 3 |
health legacy | 3 |
negative results | 3 |
infection laboratory | 3 |
new case | 3 |
national security | 3 |
accession number | 3 |
azole resistance | 3 |
threshold access | 3 |
given nitazoxanide | 3 |
genetic systems | 3 |
enteric nervous | 3 |
virological data | 3 |
sequence data | 3 |
global community | 3 |
spanish camel | 3 |
respiratory coronavirus | 3 |
disease due | 3 |
obtained samples | 3 |
pressure changes | 3 |
also reviewed | 3 |
false sense | 3 |
case numbers | 3 |
single aminoacid | 3 |
especially important | 3 |
three camels | 3 |
protecting mice | 3 |
medical observation | 3 |
children infected | 3 |
kidney cells | 3 |
seropositive individuals | 3 |
inhibition test | 3 |
participants within | 3 |
potentially exposed | 3 |
chest radiographic | 3 |
people died | 3 |
research topics | 3 |
ten cases | 3 |
triple combination | 3 |
primary effi | 3 |
thr ile | 3 |
resource settings | 3 |
pipistrellus bat | 3 |
pandemic vaccine | 3 |
new compounds | 3 |
pheic declaration | 3 |
tolllike receptor | 3 |
pipistrellus spp | 3 |
macaque model | 3 |
outbreak control | 3 |
nine symptoms | 3 |
birth defects | 3 |
ion channel | 3 |
rapid antibody | 3 |
control centre | 3 |
ective crowd | 3 |
ten patients | 3 |
might lead | 3 |
diagnostic method | 3 |
uenza complications | 3 |
ill adults | 3 |
multiple countries | 3 |
infected dromedaries | 3 |
amino acids | 3 |
years group | 3 |
ng disk | 3 |
colleagues report | 3 |
virus culture | 3 |
rapid increase | 3 |
adaptor protein | 3 |
hospital staff | 3 |
decreased lymphocytes | 3 |
epidemiological control | 3 |
community level | 3 |
undergoing bone | 3 |
viral excretion | 3 |
historical data | 3 |
without symptoms | 3 |
chemical synthesis | 3 |
vital organs | 3 |
vaccine induces | 3 |
severe pneumonia | 3 |
receptor specificity | 3 |
genetic markers | 3 |
sensitive method | 3 |
contagious agent | 3 |
dependent signalling | 3 |
colleagues screened | 3 |
randomisation lists | 3 |
draft recommendations | 3 |
paracetamol use | 3 |
clinical specimens | 3 |
multidisciplinary approach | 3 |
patients received | 3 |
double blind | 3 |
enterovirus viraemia | 3 |
super spreading | 3 |
rest day | 3 |
urinary antigen | 3 |
tablet formulation | 3 |
randomised placebo | 3 |
infected mice | 3 |
independent rt | 3 |
novel infl | 3 |
elderly patients | 3 |
reassortant viruses | 3 |
holy mosque | 3 |
exposed abattoir | 3 |
xxiii hospital | 3 |
sars virus | 3 |
years old | 3 |
yung title | 3 |
shedding patterns | 3 |
phylogenetically distinct | 3 |
transmission risk | 3 |
interspecies transmission | 3 |
plague vaccine | 3 |
might suggest | 3 |
china epidemiological | 3 |
workers will | 3 |